Helix Biopharma Corp.
HBPCF
$1.73
$1.13188.97%
OTC PK
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.50M | 1.31M | 2.72M | 2.52M | 2.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.37M | 3.87M | 7.01M | 7.26M | 7.02M |
| Operating Income | -3.37M | -3.87M | -7.01M | -7.26M | -7.02M |
| Income Before Tax | -3.47M | -3.72M | -6.89M | -7.15M | -6.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.47 | -3.72 | -6.89 | -7.15 | -6.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.47M | -3.72M | -6.89M | -7.15M | -6.85M |
| EBIT | -3.37M | -3.87M | -7.01M | -7.26M | -7.02M |
| EBITDA | -3.36M | -3.86M | -7.00M | -7.25M | -7.01M |
| EPS Basic | -0.06 | -0.07 | -0.13 | -0.14 | -0.14 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.08 | -0.09 | -0.09 |
| EPS Diluted | -0.08 | -0.09 | -0.15 | -0.17 | -0.14 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.08 | -0.09 | -0.09 |
| Average Basic Shares Outstanding | 249.87M | 223.02M | 204.26M | 193.85M | 185.76M |
| Average Diluted Shares Outstanding | 249.87M | 223.02M | 204.26M | 193.85M | 185.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |